Innovation in the fight to reduce AIDS.
Biomatrica announced today the signing of a multi-year supply agreement with a major diagnostics company in viral load testing to provide the critical reagent in the client’s sample collection device, enabling preservation and transportation of RNA in blood samples at high ambient temperatures for up to three months. The new device expands the reach of HIV testing to millions in locations remote from testing labs who lack cost-effective methods for cold transport of samples.
Biomatrica’s client is a diagnostics company participating in the UNAIDS program to diagnose 90% of all HIV positive individuals, place 90% of those diagnosed on antiretroviral therapy (ART); and achieve viral suppression in 90% of those receiving therapy.
Biomatrica’s CEO Nick Ecos sees this agreement as “further evidence that our chemical stabilization technology can be applied not only in industrialized countries, for more reliable and cost-effective transportation of emerging biomarkers, but also in developing countries where we can play an important role in simply expanding access to established methods of care.”
Biomatrica’s goal is to apply unique compound libraries, know-how, and business partnering expertise with diagnostics companies and biobanks.
This approach provides:
- Novel products for collecting and storing biomarkers
- Preserving reagents in clients’ kits
- Changing patients lives for the better
To learn more about partnering with Biomatrica, click here.